Medical research in the traditional sense is a laborious and time-consuming process. Especially in the study of Antibodies, which are a vital part of medical research. All diseases result in the production of their respective antibodies depending on the pathogen, and identifying them is key to developing a treatment for the disease.
Molcure focuses on this niche of medical research, leveraging bioinformatics and automation to assist Antibody backed drug research. The company was found in 2013 by entrepreneurs Kyono Yutaro, Ryu Ogawa, Yutaro Kyono and Yoichiro Hara, and is based in Tokyo.
Molcure -About The Company
Molcure offers an antibody screening and design platform for drug and treatment development, powered by bioinformatics and automation to support research. As a medical tool directly involved in finding cures, it is a high speed and high variation system that completes its required tasks with a high degree of accuracy and quality.
Molcure operates using the most cutting edge technology made available in house, mixing a deep knowledge of antibody biology and NGS with automated discovery systems. Using digital libraries and automation, they can accurately discover targets within a much shorter time frame.
Molcure leverages big data for storing Antibody information for research, and automation for matching and targeting the subject with their database. Their mission is to utilize these features to accelerate Antibody research and to create more effective drugs and treatments for patients.
Molcure -The Strategy
Molcure partners with research centres as well as pharmaceutical companies as their antibody screening platform of choice. They utilize their four-step strategy, containing both human and machine elements to streamline for maximum efficiency without compromising accuracy. They claim to be able to complete their mission 30 times faster than conventional means.
The first step of the process is the design of the antibody library. Using AI, they can code original peptide libraries accommodating a variation of up to 12 orders of magnitude. The second phase utilizes HAIVE, a system of interconnected, functionally independent yet cooperating modules that require minimal human involvement. This system performs advanced antibody screening. The third step involves data acquisition through biological experimentation and study. Their final step involves Abtracer, their antibody discovery program that delivers results for drugs that may be overlooked conventionally. All of these steps utilize the perfect combination of human intelligence and machine elements in harmony to provide the best results, making them the promising frontrunners of their sector.
Molcure has had 6 rounds of investments so far, raising $4.7 Million in total. The technology and the innovation involved in the firm has tremendous scope in the field of Medicine. Especially in the current scenario, the pandemic has directed much focus and investment into the Healthtech sector, particularly into fields that support drug research. A platform like Molcure which leverages cutting edge technology to benefit medical research shows great promise and potential in the current scenario.